Cash ManagementOngoing cash management efforts are encouraging, as well as the progress towards a differentiated proteomics offering.
Operational EfficiencyCost management and a 16% reduction in force should enable the cash runway to extend to 2027.
Technological DevelopmentAt close to a $0 EV with 3+ years of cash, the tech development further along than at any time in the past, addressing a large market with a differentiated approach, and a seasoned life science management team, the current stock price presents an interesting level.